New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Passage Bio, Inc.

PASG

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

3.92 0.31 +8.59%
Market cap
$11.6M
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
1.0×
Payout ratio
—

What it owns vs. what it owes Q3 FY2026, Sep 30, 2026

Shareholders’ equity is 0.24% of the balance sheet. What is a balance sheet?

Sep 30, 2026 · total $20.8M

Owns

$633.0KOther short-term assets
$20.2MCash & short-term investments

Funded by

$50.0KShareholders’ equity
$20.7MOther liabilities

Debt is 0.00% of the total; shareholders’ equity 0.24%.

Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Total current assets
20.79 25.18 34.74 47.76
Total non-current assets
— — 1.72 14.52
Total Assets
20.79 25.18 36.46 62.28
Total current liabilities
20.74 20.72 20.10 23.08
Total non-current liabilities
— — 4.61 20.44
Total liabilities
20.74 20.72 24.71 43.53
Common Equity (Total)
0.05 4.46 11.75 18.76
Shareholders Equity (Total)
0.05 4.46 11.75 18.76

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 12, 2026